from wide uptake of this publication (including Cochrane, OMERACT, IDEOM, RADS, and the GRADE Working Group).

Musculoskeletal Statistics Unit, The Parker Institute is grateful for the financial support received from public and private foundations, companies and private individuals over the years. The Parker Institute is supported by a core grant from the Oak Foundation; The Oak Foundation is a group of philanthropic organizations that, since its establishment in 1983, has given grants to not-for-profit organizations around the world.

DOI: 10.1136/annrheumdis-2020-eular.809

THU0615-HPR  FORCE-TIME CURVE ANALYSIS OF HANDGRIP STRENGTH IN PATIENTS WITH FIBROMYALGIA: COMPARISON WITH HEALTHY SUBJECTS

S. Farah1, M. Di Carlo1, F. Salaffi1, 1Hospital “Carlo Urbani” ; Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Jesi, Italy

Background: Factors associated with handgrip strength (HGs), in female with fibromyalgia (FM), use of force-time (FeT) curve to assess peak force, area under the curve (AUC), and variability of the time to reach maximum plateau of the curves (Fig. 1) (1) to identify the impact of FM patients versus healthy controls have not been extensively studied.

Objectives: The aim of the study was to compare the HGs of FM with healthy subjects and to evaluate the relationship between curve characteristics and FM disease severity (2,3).

Methods: One hundred and ten women (mean age 53.8±12.4 years; range 18 to 80) were included and compared with 111, age and BMI matched, female healthy controls. HGs was measured with an electronic device, while demographic and clinical characteristics of the subjects were obtained by the Revised version of the Fibromyalgia impact questionnaire (FIQR) and Fibromyalgia Activity Score (FAS). Multivariate regression procedure was used in order to assess the relative contribution of the covariates on the HGs.

Results: HGs-AUC and peak force levels were lower in patients with FM than healthy women (15.5 vs 11.8 kg; median was 13.9 vs 19.9, respectively; both at significant level of p<0.001) and in women with severe FM compared with those with mild-moderate FM (p<0.001). The time to reach maximum plateau of the curves was significantly higher in patients with FM than healthy women (median 342.7 vs 496.5; and in Kg median was 13.9 vs 19.9, respectively; both at significant level of p<0.001) and in women with severe FM compared with those with mild-moderate FM (p<0.001). Furthermore, a correlation was observed between widespread pain index (WPI) and peak force, AUC (both at p<0.0001), and of the time to reach maximum plateau of the curves (P=0.04) in patients with FM. Factors significantly associated with HGs-AUC in multivariate analysis were WPI and FIQR (both at p<0.001).

Conclusion: HGs is reduced in woman FM patients and is inversely related to FM severity and symptomatology. The FeT curve gave more information about grip in the FM and could be used as a complementary tool in the assessment and monitoring of FM. Further research on male FM patients is needed to confirm or contrast these findings.

Table 6. Correlations between HGs curve characteristics and questionnaires studied through the Spearman’s rho correlation coefficients (rho).

<table>
<thead>
<tr>
<th>Variable</th>
<th>FIQR</th>
<th>FAS</th>
<th>HGs peak force levels</th>
<th>HGs-AUC of the curves</th>
</tr>
</thead>
<tbody>
<tr>
<td>WPI</td>
<td>0.732</td>
<td>0.823</td>
<td>-0.612</td>
<td>-0.195 0.0415 0.615</td>
</tr>
<tr>
<td>FIQR</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>FAS</td>
<td>0.761</td>
<td>0.576</td>
<td>-0.054 0.5768 0.592</td>
<td></td>
</tr>
<tr>
<td>HGs peak force levels</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HGs-AUC of the curves</td>
<td>&lt;0.151 0.0249 &lt;0.615</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Figure 1. Force–time (FeT) curve showing the method of calculation of the various force attributes.

Disclosures of Interests: None declared

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.4197

THU0616-HPR  EXPIRATORY FLOW ACCELERATOR (EFA) IN SYSTEMIC SCLEROSIS PATIENTS WITH MUCUS HYPERSECRETION, PRODUCTIVE COUGH AND DYSPNEA: PRELIMINARY RESULTS FROM A HOME-BASED AIRWAY CLEARANCE TECHNIQUE DAILY PROGRAM

S. Faverzani1, A. Becciolini1, E. Crisafulli2, F. Nocera1, E. Di Donato3, F. Mozzani1, M. Riva1, D. Santilli1, L. Monica1, A. Barbieri3, L. Barone3, M. Marvisi3, V. Alfieri1, A. Frizzelli1, A. Chetta1, A. Ariani1, 1Azienda Ospedaliero Universitaria di Parma, Parma, Italy; 2Azienda Ospedaliero Universitaria Integrata Verona, Verona, Italy; 3Azienda Ospedaliero Universitaria di Parma, Parma, Italy; 4Casa di Cura Figlie di San Camillo, Cremona, Italy

Background: Systemic sclerosis (SSc) is a chronic disease with frequent lung involvement. As mucoiary clearance is impaired, mucus retention and frequent pulmonary infections, increase morbidity and mortality (1). Airway clearance techniques (ACT) enhance removal of mucus from the airways. Expiratory flow accelerator (EFA) is a new technology that promotes deep and gentle drainage of the bronchial secretions, through the Venturi effect. No respiratory effort is required and no negative pressure is generated, avoiding risk of bronchial collapse (2).

Objectives: The aim of this study was to describe the effectiveness of EFA in improving pulmonary symptoms in SSc patients.

Methods: SSc patients with daily productive cough, frequent pulmonary exacerbations, exertional dyspnea and/or reduced physical activity were selected. All of them underwent a home-based ACT program with EFA. A Respiratory Physiotherapist (RT) trained each patient to use the device 3 times a day, 15 minutes each session. Every subject compiled the Saint George’s Respiratory Questionnaire (SGRQ) and scleroderma Health Assessment Questionnaire (SHAQ) at baseline, 30, 90 and 180 days from the beginning. Statistical analysis has been carried out with General linear model for repeated measures. A value of p<0.05 was considered statistically significant.

Results: 8 patients were enrolled (M:F=1:7), median age 54 (IQR=58; 46-69) years. Interstitial lung disease affected the majority of them (7/8). SGRQ total score and SHAQ domain for respiratory symptoms decreased over time.